Counselors in Prichard, AL Accepting Medicare
4 Counselors found. Showing 1 - 4
 Ms. Cecelia Delphine Johnson, LMFT Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1111 W Clark Ave, Prichard, AL 36610 Phone: 251-751-2812 |
Ms. Carrie L Hubbard, COUNSELOR Counselor Medicare: Not Enrolled in Medicare Practice Location: 510 S Wilson Ave, Prichard, AL 36610 Phone: 251-301-7011 Fax: 251-452-1598 |
Ms. Vanessa R Thompson, COUNSELOR Counselor Medicare: Not Enrolled in Medicare Practice Location: 510 S Wilson Ave, Prichard, AL 36610 Phone: 251-301-7011 Fax: 251-452-1598 |
Demeka Lasherry Buck Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1302 Saint Stephens Rd, Prichard, AL 36610 Phone: 251-510-3950 |
News Archive
First Edition: September 7, 2012
Now on Kaiser Health News' blog, Sarah Varney reports on California Gov. Jerry Brown, his absence from the Democratic convention and efforts to implement the health law: "California's Jerry Brown, the governor of the most populous state in the union, a state that has aggressively pushed ahead with the Affordable Care Act even when it wasn't the "in-thing," is sitting out this year's Democratic National Convention.
Repeated sleep loss affects ability to compensate for lost sleep
We've all experienced that occasional all-too-short night of sleep - staying out too late at a party on a weeknight, studying into the wee hours for a morning exam or being kept up during the night with a sick child.
People with MS who relapse within first five years of onset have more severe disability: Study
People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.
Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI
Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0 in favor of approval for complicated skin and skin structure infections (cSSSI).
› Verified 9 days ago